44 related articles for article (PubMed ID: 29700766)
21. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
22. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs.
Chai R; Gao H; Ma Z; Guo M; Fu Q; Liu H; He Z
Curr Drug Deliv; 2019; 16(6):500-510. PubMed ID: 31244438
[TBL] [Abstract][Full Text] [Related]
23. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation.
B A; D N; Veerabrahma K
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):126-137. PubMed ID: 28290712
[TBL] [Abstract][Full Text] [Related]
24. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
[TBL] [Abstract][Full Text] [Related]
25. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
Jain S; Patel K; Arora S; Reddy VA; Dora CP
Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
[TBL] [Abstract][Full Text] [Related]
26. Nanosuspension: A Formulation Technology for Tackling the Poor Aqueous Solubility and Bioavailability of Poorly Soluble Drugs.
Elsebay MT; Eissa NG; Balata GF; Kamal MA; Elnahas HM
Curr Pharm Des; 2023; 29(29):2297-2312. PubMed ID: 37694786
[TBL] [Abstract][Full Text] [Related]
27. An overview of recent patents on nanosuspension.
Modh N; Mehta D; Parejiya P; Popat A; Barot B
Recent Pat Drug Deliv Formul; 2014; 8(2):144-54. PubMed ID: 24758487
[TBL] [Abstract][Full Text] [Related]
28. Nanosuspension-Based Drug Delivery Systems for Topical Applications.
Aldeeb MME; Wilar G; Suhandi C; Elamin KM; Wathoni N
Int J Nanomedicine; 2024; 19():825-844. PubMed ID: 38293608
[TBL] [Abstract][Full Text] [Related]
29. [Research progress on
Shen BD; Shen CY; Xu LX; Zhu WF; Yuan HL
Zhongguo Zhong Yao Za Zhi; 2018 Oct; 43(19):3828-3833. PubMed ID: 30453705
[TBL] [Abstract][Full Text] [Related]
30. Recent Advances in Nanosuspension Technology for Drug Delivery.
Arora D; Khurana B; Rath G; Nanda S; Goyal AK
Curr Pharm Des; 2018; 24(21):2403-2415. PubMed ID: 29788880
[TBL] [Abstract][Full Text] [Related]
31. Emerging Potential of Nanosuspension-Enabled Drug Delivery: An Overview.
Silki ; Sinha VR
Crit Rev Ther Drug Carrier Syst; 2015; 32(6):535-57. PubMed ID: 26559552
[TBL] [Abstract][Full Text] [Related]
32. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Alsofany JM; Hamza MY; Abdelbary AA
AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
